Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.
Blank, C ; ; Schachter, J ; Robert, C ; Ribas, A ; Long, G ; Arance, A ; Mortier, L ; Daud, A ; Carlino, M ... show 10 more
Blank, C
Schachter, J
Robert, C
Ribas, A
Long, G
Arance, A
Mortier, L
Daud, A
Carlino, M
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. 2016, 26: E117-E118 Melanoma Res